AIM
IMDZ

Acrospire Investment Management’s Immune Design Corp. IMDZ Stock Holding History

Acrospire Investment Management’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-741
Closed -$7K – 2113
2017
Q2 		$7K Buy
+741
New +$5.2K 0.01% 1912
2017
Q1 		– Sell
-662
Closed -$4K – 2739
2016
Q4 		$4K Buy
+662
New +$4.68K ﹤0.01% 2095

Other funds holding IMDZ

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DAM
Doheny Asset Management Los Angeles, California $153M AUM 42.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Acrospire Investment Management's IMDZ Position: Q3 2017 in Review

Acrospire Investment Management sold out of Immune Design Corp. (IMDZ) in Q3 2017, closing a stake of 741 shares — an estimated $7K sold.

Acrospire Investment Management first reported a position in IMDZ in Q4 2016 and held it in 2 quarters. The position peaked at $7K in Q2 2017. 65 funds tracked by Wall St. Rank hold IMDZ as of Q3 2017.

  • Acrospire Investment Management reported no remaining Immune Design Corp. position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 741 Immune Design Corp. shares in Q3 2017, an estimated $7K.
  • Acrospire Investment Management first reported a position in Immune Design Corp. in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Immune Design Corp. position peaked at $7K in Q2 2017.
  • 65 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.